Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland

BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved for use in breast cancer susceptibility gene (BRCA)-mutated metastatic castration-resistant prostate cancer (mCPRC) patients. Our aim was to evaluate the adverse events (AEs) and efficacy of Olaparib in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jian, Ye, Dingwei, Zhu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520412/
https://www.ncbi.nlm.nih.gov/pubmed/36225282
http://dx.doi.org/10.1016/j.prnil.2022.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520412/
https://www.ncbi.nlm.nih.gov/pubmed/36225282
http://dx.doi.org/10.1016/j.prnil.2022.04.005

Ejemplares similares